Analysts have been eager to weigh in on the Healthcare sector with new ratings on Trevena (TRVN – Research Report), Akebia Therapeutics (AKBA – Research Report) and Fennec Pharmaceuticals (FENC – Research Report).
Trevena (TRVN)
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Trevena, with a price target of $9.00. The company’s shares closed last Thursday at $0.70.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Trevena has an analyst consensus of Moderate Buy, with a price target consensus of $5.50, a 587.5% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $2.00 price target.
See the top stocks recommended by analysts >>
Akebia Therapeutics (AKBA)
In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Akebia Therapeutics, with a price target of $1.25. The company’s shares closed last Thursday at $0.56, close to its 52-week low of $0.24.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Currently, the analyst consensus on Akebia Therapeutics is a Hold with an average price target of $1.25.
Fennec Pharmaceuticals (FENC)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Fennec Pharmaceuticals today and set a price target of $18.00. The company’s shares closed last Thursday at $8.55.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Fennec Pharmaceuticals is a Strong Buy with an average price target of $15.67, which is a 90.9% upside from current levels. In a report issued on March 27, Craig-Hallum also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TRVN:
- Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
- Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study
- Trevena Inc. (TRVN) Q4 Earnings Cheat Sheet
- Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
- Trevena initiates Phase 1 proof-of-concept study of TRV045
